Obermeyer财富伙伴公司削减了辉瑞公司的股份,因为该公司没有达到 " Q1 " 收入目标,但没有达到 " EPS " 估计值。 Obermeyer Wealth Partners cut Pfizer holdings as the company missed Q1 revenue targets but beat EPS estimates.

Obermeyer财富伙伴公司将其在辉瑞公司的持有量减少了3.6%,而辉瑞公司的市场上限为1 312.5亿美元,红利收益为7.45%。 Obermeyer Wealth Partners reduced its holdings in Pfizer Inc. by 3.6%, while Pfizer's market cap stands at $131.25 billion with a dividend yield of 7.45%. Pfizer的2025年Q1收入显示,收入下降了7.8%,降至137.2亿美元(缺失估计数字),但EPS为0.92美元,高于预期。 Pfizer's Q1 2025 earnings showed a 7.8% revenue drop to $13.72 billion, missing estimates, but the EPS was $0.92, beating expectations. 该公司把重点放在管道生产率和效率上,目标是到2025年节省45亿美元的费用。 The company is focusing on pipeline productivity and efficiency, aiming for $4.5 billion in cost savings by 2025. 分析师对股票有“机动购买”共识,价格目标是29.17美元。 Analysts have a "Moderate Buy" consensus on the stock, with a price target of $29.17.